Figure 5From: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer Five-year relative survival for node-negative cases within the St Gallen intermediate risk group (intermediate risk 2) according to the ER/PR/HER2 subtypes.Back to article page